CDKL5 and craniodiaphyseal dysplasia: It is intriguing to speculate that CDKL5 is not only able to control its own activity, but that mutations in CDD patients might also lead to a loss in CDKL5 catalytic output through a lack of activation‐loop Tyr phosphorylation.